血小板和补体的关系研究进展

doi:10.3969/j.issn.1673-8640.2026.07.016

检验医学 ›› 2026, Vol. 41 ›› Issue (7): 708-713.DOI: 10.3969/j.issn.1673-8640.2026.07.016

血小板和补体的关系研究进展

于梦瑶¹, 王春艳², 乔蕊³, 黄声凯¹, 龚恒文¹, 崔婵娟¹()

¹ 国家癌症中心国家肿瘤临床医学研究中心中国医学科学院北京协和医学院肿瘤医院检验科，北京 100021
² 山西省肿瘤医院中国医学科学院肿瘤医院山西医院山西医科大学附属肿瘤医院医学检验部，山西太原 030013
³ 北京大学第三医院检验科，北京 100191

收稿日期:2025-04-25 修回日期:2025-08-01 出版日期:2026-07-30 发布日期:2026-07-23
通讯作者: 崔婵娟，E-mail：chanjuancui@126.com。
作者简介:于梦瑶，女，1992年生，学士，初级检验师，主要从事血栓与止血相关研究。
基金资助:
国家自然科学基金项目(82302602);国家重点研发计划项目(2022YFC3602301)

Research progress on the relationship between platelets and complements

YU Mengyao¹, WANG Chunyan², QIAO Rui³, HUANG Shengkai¹, GONG Hengwen¹, CUI Chanjuan¹()

¹ Department of Clinical Laboratory， the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College， Beijing 100021， China
² Department of Clinical Laboratory， Shanxi Province Cancer Hospital/Cancer Hospital Affiliated to Shanxi Medical University/Shanxi Hospital Affiliated to Cancer Hospital，Chinese Academy of Medical Sciences，Taiyuan 030013， Shanxi， China
³ Department of Clinical Laboratory， Peking University Third Hospital， Beijing 100191， China

Received:2025-04-25 Revised:2025-08-01 Online:2026-07-30 Published:2026-07-23

摘要/Abstract

摘要：

免疫系统激活与血栓形成之间存在着复杂的联系，特别是先天免疫反应中的补体系统。补体系统是免疫系统的一部分，除提供天然防御和介导炎症反应外，还与血小板活化和血栓形成存在联系。补体系统中的一些成分，如补体C3、C5、攻膜复合体，可参与调节血小板活化和血栓形成，且活化的血小板还会进一步激活补体系统。然而，这种相互作用的机制仍需进一步探索。文章对近年来血小板和补体的关系相关研究，以及这种关系在以血栓形成和补体激活为特征的疾病中的作用进行综述。

关键词: 血小板, 补体, 血栓, 免疫反应, 疾病

Abstract:

There is a complex relationship between immune system activation and thrombosis，especially in the complement system of the innate immune response. The complement system is a part of the immune system，not only providing natural defense and mediating inflammatory responses，but also being associated with the activation of platelets and thrombosis. Some components of the complement system，such as complement 3（C3），complement 5（C5） and membrane attack complex，can participate in regulating platelet activation and thrombosis，and activated platelets will further activate the complement system. However，the mechanism of this interaction still needs further exploration. This review focuses on the research on the relationship between platelets and complements in recent years，as well as the role of this relationship in diseases characterized by thrombosis and complement activation.

Key words: Platelet, Complement, Thrombosis, Immune response, Disease

中图分类号:

R446.11

于梦瑶, 王春艳, 乔蕊, 黄声凯, 龚恒文, 崔婵娟. 血小板和补体的关系研究进展[J]. 检验医学, 2026, 41(7): 708-713.

YU Mengyao, WANG Chunyan, QIAO Rui, HUANG Shengkai, GONG Hengwen, CUI Chanjuan. Research progress on the relationship between platelets and complements[J]. Laboratory Medicine, 2026, 41(7): 708-713.

图/表 2

参考文献 46

[1]	Jurk K, Kehrer B E. Platelets:physiology and biochemistry[J]. Semin Thromb Hemost, 2024, 50(5):794-803. DOI URL
[2]	Rawish E, Nording H, Münte T, et al. Platelets as mediators of neuroinflammation and thrombosis[J]. Front Immunol, 2020, 11:548631. DOI URL
[3]	Huilcaman R, Venturini W, Fuenzalida L, et al. Platelets,a key cell in inflammation and atherosclerosis progression[J]. Cells, 2022, 11(6):1014. DOI URL
[4]	Mcmurray J C, Schornack B J, Weskamp A L, et al. Immunodeficiency:complement disorders[J]. Allergy Asthma Proc, 2024, 45(5):305-309. DOI URL
[5]	Coss S L, Zhou D, Chua G T, et al. The complement system and human autoimmune diseases[J]. J Autoimmun, 2023, 137:102979. DOI URL
[6]	Ghebrehiwet B, Geisbrecht B V, Xu X, et al. The C1q receptors:focus on gC1qR/p33(C1qBP,p32,HABP-1)1[J]. Semin Immunol, 2019, 45:101338. DOI URL
[7]	Linge C P, Jern A, Tydén H, et al. Enrichment of complement,immunoglobulins,and autoantibody targets in the proteome of platelets from patients with systemic lupus erythematosus[J]. Thromb Haemost, 2022, 122(9):1486-1501. DOI URL
[8]	Delila L, Wu Y W, Nebie O, et al. Extensive characterization of the composition and functional activities of five preparations of human platelet lysates for dedicated clinical uses[J]. Platelets, 2021, 32(2):259-272. DOI PMID
[9]	Hamad O A, Ekdahl K N, Nilsson P H, et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets[J]. J Thromb Haemost, 2008, 6(8):1413-1421. DOI PMID
[10]	Dobó J, Kocsis A, Farkas B, et al. The lectin pathway of the complement system-activation,regulation,disease connections and interplay with other(proteolytic) systems[J]. Int J Mol Sci, 2024, 25(3):1566. DOI URL
[11]	Golomingi M, Kohler J, Jenny L, et al. Complement lectin pathway components MBL and MASP-1 promote haemostasis upon vessel injury in a microvascular bleeding model[J]. Front Immunol, 2022, 13:948190. DOI URL
[12]	Thurman J M, Fremeaux-bacchi V. Alternative pathway diagnostics[J]. Immunol Rev, 2023, 313(1):225-238. DOI URL
[13]	De Bont C M, Boelens W C, Pruijn G J M. NETosis,complement,and coagulation:a triangular relationship[J]. Cell Mol Immunol, 2019, 16(1):19-27. DOI
[14]	Del Conde I, Crúz M A, Zhang H, et al. Platelet activation leads to activation and propagation of the complement system[J]. J Exp Med, 2005, 201(6):871-879. DOI PMID
[15]	Saggu G, Cortes C, Emch H N, et al. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H₂O)[J]. J Immunol, 2013, 190(12):6457-6467. DOI PMID
[16]	Hamad O A, Mitroulis I, Fromell K, et al. Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18[J]. Thromb Haemost, 2015, 114(6):1207-1217. DOI URL
[17]	Mishra N, Mohata M, Narang R, et al. Altered expression of complement regulatory proteins CD35,CD46,CD55,and CD59 on leukocyte subsets in individuals suffering from coronary artery disease[J]. Front Immunol, 2019, 10:2072. DOI URL
[18]	Sauter R J, Sauter M, Reis E S, et al. Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis[J]. Circulation, 2018, 138(16):1720-1735. DOI PMID
[19]	Mickael C, Jordan M, Posey J N, et al. Activation of platelets and the complement system in mice with Schistosoma-induced pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2024, 327(5):L661-L668.
[20]	任贵生, 陈文萃. 补体与急性肾损伤[J]. 肾脏病与透析肾移植杂志, 2018, 27(5):468-472.
[21]	Mannes M, Pechtl V, Hafner S, et al. Complement and platelets:prothrombotic cell activation requires membrane attack complex-induced release of danger signals[J]. Blood Adv, 2023, 7(20):6367-6380. DOI PMID
[22]	Noris M, Galbusera M. The complement alternative pathway and hemostasis[J]. Immunol Rev, 2023, 313(1):139-161. DOI URL
[23]	Eriksson O, Mohlin C, Nilsson B, et al. The human platelet as an innate immune cell:interactions between activated platelets and the complement system[J]. Front Immunol, 2019, 10:1590. DOI PMID
[24]	Kohli S, Shahzad K, Jouppila A, et al. Thrombosis and inflammation-a dynamic interplay and the role of glycosaminoglycans and activated protein C[J]. Front Cardiovasc Med, 2022, 9:866751. DOI URL
[25]	Karasu E, Demmelmaier J, Kellermann S, et al. Complement C5a induces pro-inflammatory microvesicle shedding in severely injured patients[J]. Front Immunol, 2020, 11:1789. DOI PMID
[26]	Brown N, Sullo N, Tyson N, et al. Acute kidney injury after cardiac surgery is associated with platelet activation[J]. J Thromb Haemost, 2025, 23(9):2776-2789. DOI PMID
[27]	Taus F, Salvagno G, Canè S, et al. Platelets promote thromboinflammation in SARS-CoV-2 pneumonia[J]. Arterioscler Thromb Vasc Biol, 2020, 40(12):2975-2989. DOI PMID
[28]	Gauer J S, Ajjan R A, Ariëns R A S. Platelet-neutrophil interaction and thromboinflammation in diabetes:considerations for novel therapeutic approaches[J]. J Am Heart Assoc, 2022, 11(20):e027071. DOI URL
[29]	Lappegård K T, Fung M, Bergseth G, et al. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation[J]. Ann Thorac Surg, 2004, 77(3):932-941. PMID
[30]	Loeven M A, Maciej-hulme M L, Yanginlar C, et al. Selective binding of heparin/heparan sulfate oligosaccharides to factor H and factor H-related proteins:therapeutic potential for C3 glomerulopathies[J]. Front Immunol, 2021, 12:676662. DOI URL
[31]	Blatt A Z, Saggu G, Cortes C, et al. Factor H C-terminal domains are critical for regulation of platelet/granulocyte aggregate formation[J]. Front Immunol, 2017, 8:1586. DOI PMID
[32]	Wang Y, Miao Y, Gong K, et al. Plasma complement protein C3a level was associated with abdominal aortic calcification in patients on hemodialysis[J]. J Cardiovasc Transl Res, 2019, 12(5):496-505. DOI PMID
[33]	吴嘉, 汪俊军. 补体系统在动脉粥样硬化性心血管疾病中的研究与应用[J]. 中华检验医学杂志, 2020, 43(9):855-859.
[34]	Li H, Sun K, Zhao R, et al. Inflammatory biomarkers of coronary heart disease[J]. Front Biosci(Schol Ed), 2018, 10(1):185-196.
[35]	Wenzel U O, Kemper C, Bode M. The role of complement in arterial hypertension and hypertensive end organ damage[J]. Br J Pharmacol, 2021, 178(14):2849-2862. DOI URL
[36]	Zhang X, Yin J, Shao K, et al. High serum complement component C4 as a unique predictor of unfavorable outcomes in diabetic stroke[J]. Metab Brain Dis, 2021, 36(8):2313-2322. DOI PMID
[37]	Rawish E, Sauter M, Sauter R, et al. Complement,inflammation and thrombosis[J]. Br J Pharmacol, 2021, 178(14):2892-2904. DOI URL
[38]	Yerigeri K, Kadatane S, Mongan K, et al. Atypical hemolytic-uremic syndrome:genetic basis,clinical manifestations,and a multidisciplinary approach to management[J]. J Multidiscip Healthc, 2023, 16:2233-2249. DOI PMID
[39]	Fakhouri F, Schwotzer N, Frémeaux-bacchi V. How I diagnose and treat atypical hemolytic uremic syndrome[J]. Blood, 2023, 141(9):984-995. DOI URL
[40]	王乐宇, 胡青林, 陈苗, 等. 依库珠单抗治疗溶血性阵发性睡眠性血红蛋白尿症的中国真实世界研究[J]. 中华血液学杂志, 2024, 45(2):184-189.
[41]	Antonucci L, Thurman J M, Vivarelli M. Complement inhibitors in pediatric kidney diseases:new therapeutic opportunities[J]. Pediatr Nephrol, 2024, 39(5):1387-1404. DOI
[42]	Dai X, Ma Y, Lin Q, et al. Clinical features and management of atypical hemolytic uremic syndrome patient with DGKE gene variants:a case report[J]. Front Pediatr, 2023, 11:1162974. DOI URL
[43]	Szlendak U, Budziszewska B, Spychalska J, et al. Paroxysmal nocturnal hemoglobinuria:advances in the understanding of pathophysiology,diagnosis,and treatment[J]. Pol Arch Intern Med, 2022, 132(6):16271.
[44]	Kokoris S, Polyviou A, Evangelidis P, et al. Thrombosis in paroxysmal nocturnal hemoglobinuria(PNH):from pathogenesis to treatment[J]. Int J Mol Sci, 2024, 25(22):12104. DOI URL
[45]	李丽燕, 付蓉. 阵发性睡眠性血红蛋白尿症诊断与治疗中国指南(2024年版)解读[J]. 中华血液学杂志, 2024, 45(12):1071-1077.
[46]	Brodsky R A. How I treat paroxysmal nocturnal hemoglobinuria[J]. Blood, 2021, 137(10):1304-1309. DOI PMID

血小板和补体的关系研究进展

Research progress on the relationship between platelets and complements

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 46

相关文章 15

编辑推荐

Metrics

[1]	黄峥, 王闻卿, 徐阳, 林征, 张岭, 韩卓伟, 王亚楠, 许学斌. 不典型姆班达卡沙门菌ST413腹泻1例报道[J]. 检验医学, 2026, 41(7): 719-722.
[2]	李本柏, 鄢盛恺. 临床血脂检测的规范化——从指南到实践[J]. 检验医学, 2026, 41(6): 517-520.
[3]	王小铃, 施清喻, 周佳烨, 王扣琼, 朱晶, 沈逸枫, 邵文琦, 潘柏申, 王蓓丽, 郭玮. ASCVD患者公式法LDL-C估算结果与均相酶法LDL-C直接检测结果的一致性[J]. 检验医学, 2026, 41(6): 521-529.
[4]	杨琳, 卢仁泉, 郭林, 仲瑷玲. ATYP.C在膀胱癌辅助诊断中的价值及其与MTHFR基因型的相关性[J]. 检验医学, 2026, 41(5): 452-458.
[5]	王源, 陈丹, 黄娜. 基于MIMIC-Ⅳ数据库数据分析红细胞分布宽度/血小板计数比值预测ARDS患者短期预后的价值[J]. 检验医学, 2026, 41(4): 362-368.
[6]	王向辉, 李小芹, 薛福敏. 血清TNF-α、hs-CRP、IL-22在儿童克罗恩病疾病活动度和预后评估中的作用[J]. 检验医学, 2026, 41(4): 386-390.
[7]	郭郑斌, 胡莉娜, 张睿, 陈洁, 张静, 但刚. 基于多指标构建自身免疫性疾病患者血栓发生预测模型及其临床应用评价[J]. 检验医学, 2026, 41(3): 239-244.
[8]	蔡眉, 王佳余, 顾丹凤, 何佳亮, 周丽芳, 杨海鸥. 凝血和纤溶指标联合血栓弹力图预测孕产妇静脉血栓栓塞风险的效能[J]. 检验医学, 2026, 41(3): 272-277.
[9]	张辉, 袁靖雯, 张驰. 武汉地区成人荧光法血小板计数和血小板相关参数参考区间调查[J]. 检验医学, 2025, 40(9): 892-896.
[10]	陈文丽, 金成, 周露露, 徐卫益. MicroR在指导血小板计数复检中的应用[J]. 检验医学, 2025, 40(9): 897-900.
[11]	赵君, 王鹏. 基于血常规指标和NLR、PLR、MLR诊断儿童腺病毒感染[J]. 检验医学, 2025, 40(8): 817-820.
[12]	李飞, 易长林, 金佩佩, 王芳, 丁宁. 纤维蛋白原/白蛋白比值在SLE疾病活动度和LN诊断中的临床价值[J]. 检验医学, 2025, 40(7): 654-659.
[13]	姜风英, 姜云, 米瑞, 钱希铭, 王秋波. 老年糖尿病足溃疡患者血小板和凝血功能指标变化及其临床意义[J]. 检验医学, 2025, 40(7): 708-712.
[14]	王丽, 唐玲, 金亚雄, 张君龙, 高雪丹, 牛倩. LDH、MO#和LMR在RA-ILD鉴别诊断中的价值[J]. 检验医学, 2025, 40(6): 525-533.
[15]	王小波. 167 202例临床样本抗核抗体检测结果回顾性分析[J]. 检验医学, 2025, 40(6): 583-591.